Introduction {#sec1}
============

The widespread incidence of multidrug-resistant pathogens constitutes a major clinical problem.[@bib1] Additionally, complications associated with bacterial infection arise due to irreversible bacterial adhesion to either living or nonliving surfaces, especially in deep-seated surfaces of medical devices such as catheters.[@bib2] Adhesion of bacteria begins with the formation of extracellular biopolymers which result in the formation of a biofilm. Embedded microbes inside the formed biofilm matrix are characterized by high growth rates and elevated resistance to conventional antimicrobial therapy.[@bib3] Different antimicrobial agents and delivery strategies for existing antibiotics have been explored to counteract the developed resistance.[@bib4]

Nanotechnology is a new strategy in the antimicrobial field that is being developed to put an end to resistant microbes.[@bib1] In general, nanoparticle forms of such metals as platinum, silver, copper, and gold have antimicrobial activities against various pathogenic bacteria and fungi. Specifically, silver nanoparticles have promising applications in nanotechnology and nanomedicine and have been approved for their bactericidal activity against broad spectrum bacterial infections as well as for their fungicide effects against pathogenic fungi such as *Aspergillus* and *Candida*.[@bib5] Additionally, silver nanoparticles possess antiviral effects against HIV-1.[@bib6] These nanosize particles also assist in wound healing and treat the associated infections.[@bib7] Recently, silver nanoparticles have been shown to eliminate microorganisms on textile fabrics[@bib8] and to inhibit biofilm formation.[@bib9] Additionally, silver nanoparticles have been reported to be biocompatible drug delivery nanocarriers,[@bib10] and soft-tissue friendly dental implants[@bib11] both *in vitro* and *in vivo*.[@bib10], [@bib11]

Several chemical[@bib12], [@bib13] and physical methods were developed for the preparation of silver nanoparticles. The natural green synthesis approach is an eco-friendly and cost-effective biosynthesis method for silver nanoparticles. This biological method of production is usually accomplished using bacteria, fungi or plant extracts. The bacterial enzymes and metabolites ensure rapid and consistent reduction of silver ions to their element form. Interestingly, the use of microorganism extract has resulted in an easy method to synthesize nanoparticles with characteristic shapes, size and morphology.[@bib14]

Therefore, in this study, we assessed the antimicrobial and anti-biofilm activities of silver nanoparticles synthesized using nonpathogenic *Acinetobacter baumannii* bacterial extract. We evaluated the synthesized nanoparticles using transmission electron microscopy (TEM), and analysed their particle size and zeta potential. We evaluated the antimicrobial and adhesive activities of the nanoparticles against multidrug-resistant Gram-negative isolates from urinary tract infections.

Materials and Methods {#sec2}
=====================

Bacterial strains and cultivation conditions {#sec2.1}
--------------------------------------------

The bacterial isolate *Acinetobacter baumannii* (non-pathogenic) was provided by Prof. Abd El-Rahman, faculty of pharmacy, microbiology department, El-Azhar University. *Klebsiella pneumoniae*, *Pseudomonas aeruginosa,* and *Escherichia coli* isolates were purified from urine samples collected from Mansoura University Hospitals. The isolates were identified using the automated identification system, VITEK 2 (bioMerieux, Marcy I\'Etoile, France). Antibiotic susceptibility of the isolates was also determined according to clinical laboratory standards.[@bib15] Antibiotic susceptibility was assessed and compared to different classes of antimicrobial agents such as ampicillin (AP), amoxicillin/clavulanic acid (AUG), amikacin (AK), aztreonam (ATM), cefoxitin (FOX), ceftazidime (CAZ), ciprofloxacin (CIP), cotrimoxazole (TS), piperacillin (PRL), gentamicin (GM) and imipenem (IMI).

All bacterial isolates were cultivated in Luria--Bertani (LB) broth containing: yeast extract 0.5%w/v, tryptone 1% and sodium chloride 1% with pH 6.8. A stock solution of AgNO~3~ 10 mM in sterile distilled water was prepared and stored at 4 °C. Amoxicillin/clavulanic acid (Glaxo SmithKline, UK) was used as a positive control.

Synthesis of silver nanoparticles {#sec2.2}
---------------------------------

Luria--Bertani medium in Erlenmeyer flasks (50 ml) were inoculated with freshly grown inoculums of *A. baumannii*. The culture flasks were incubated for 24 h at 37 °C. The cultures were centrifuged at 6.000 ×*g* (Hettich Zentrifugen, Germany) and the supernatants were filtered twice using syringe filters (0.45 μm) (Macherey--Nagel, US). The cell-free filtrates were mixed with AgNO~3~ to a final concentration of 1 mM. The silver nanoparticles thus obtained were confirmed through observed colour change, changes in the surface plasmon resonance, and visible light spectroscopy measurements measured between 200 and 800 nm (Evolution 201 UV--visible spectrophotometer, Thermo Scientific). The control samples containing AgNO~3~ 1 mM without bacterial cultures were also prepared.[@bib16]

Characterization of the prepared silver nanoparticles {#sec2.3}
-----------------------------------------------------

### Transmission electron microscopy (TEM) {#sec2.3.1}

The synthesis of silver nanoparticles was monitored visually by colour change after the addition of AgNO~3~. The formed silver nanoparticles were analysed using TEM (JEM-2100, JEOL, UK). Briefly, the carbon grid was mounted with one drop of bacterial filtrates containing silver nanoparticles. Silver nanoparticles were photographed at a magnification power of 60.000--80.000 and size scale range of 50--200 nm.[@bib16]

### Particle size analysis and zeta potential measurement {#sec2.3.2}

The particle size distribution was assessed using a computer controlled particle size analyser (Nano ZS90, Malvern, UK). The average particle size, size distribution, and zeta potentials were calculated using a Java image tool.

### Antibacterial activity of the prepared silver nanoparticles {#sec2.3.3}

The minimum inhibitory concentration (MIC) of the prepared silver nanoparticles from *A. baumannii* was quantified using the microtiter plate assay method.[@bib15] Twofold serial dilutions of the obtained particles were prepared. Each well was inoculated with 5 × 10^6^ CFU of the test organisms (*E. coli, P. aeruginosa*, and *K. pneumoniae*). The antibacterial activity of amoxicillin/clavulanic acid was estimated and used as a positive control. The microtiter plates were incubated at 37 °C for 18 h. The minimal inhibitory concentration was assigned to the lowest concentration that inhibited visible microbial growth.

### Effect of silver nanoparticles on bacterial attachment {#sec2.3.4}

The effects of the synthesised silver nanoparticles on microbial adhesion and biofilm formation were evaluated using the microtiter plate method.[@bib17] Briefly, 100 μl of growth medium containing silver nanoparticles (1/4 MIC) was transferred to each well. Overnight cultures of the test bacteria were diluted, and 10 μl samples were added to the corresponding wells to obtain a final concentration of 5 × 10^6^ CFU/well and the plates were incubated for 24 h. Microbial controls without silver nanoparticles were cultured under the same conditions.

On the second day, the wells were aspirated and the attached cells were washed twice using 150 μl of sterile saline to remove the free 'planktonic' bacteria. The adherent biofilm in each well was fixed with methanol for 15 min. The wells were stained with crystal violet (1%, w/v). The plates were washed with distilled water and dried completely. Finally, glacial acetic acid (33%) was added to each well to dissolve the adherent bacteria and the OD at 490 nm was measured using a microtitre ELISA reader (Microplate reader, Perlong Medical Equipment Co., Ltd., China). Percentage inhibition of biofilm formation was calculated as follows: \[(OD~490~ control untreated sessile cells -- OD~490~ cells treated with Ag nanoparticles)/OD~490~ control untreated sessile cells\].

### Statistical analyses {#sec2.3.5}

MIC and biofilm values were calculated from the mean of three separate experiments using Microsoft Excel and expressed as the mean ± standard deviation. Statistical analysis was conducted using GraphPad Instate software package (version 3.05), Tukey--Kramer multiple-comparison test and the differences were considered significant when *p* \< 0.01.

Results {#sec3}
=======

Biosynthesis of silver nanoparticles {#sec3.1}
------------------------------------

The formation of silver nanoparticles using microbial sources was visually monitored. A change in the colour of the reaction mixtures containing AgNO~3~ and bacterial supernatants was considered to be the primary indicator of silver nanoparticles formation ([Figure 1](#fig1){ref-type="fig"}). The formation of nanoparticles was also monitored by measuring absorption spectra. A change in the colour of AgNO~3~ solution as well as the appearance of an absorption peak at 390 nm ([Figure 2](#fig2){ref-type="fig"}), confirms the synthesis of silver nanoparticles.Figure 1Colour change of cell-free supernatants of *A. baumannii* from pale yellow to dark brown after treatment with AgNO~3~.Figure 1Figure 2Absorption spectra demonstrating the surface plasmon peaks at 390 nm for the synthesized silver nanoparticles.Figure 2

Transmission electron microscopy {#sec3.2}
--------------------------------

Images of the silver nanoparticles are shown in [Figure 3](#fig3){ref-type="fig"}. As shown, the TEM indicated that the silver nanoparticles were dispersed in the supernatant and had a spherical shape.Figure 3Transmission electron images of the synthesized silver nanoparticles from *Acinetobacter* with scales 100 nm and 50 nm.Figure 3

Particle size analysis and zeta potential {#sec3.3}
-----------------------------------------

The particle size distribution of the synthesized nanoparticles was 37--168 nm ([Figure 4](#fig4){ref-type="fig"}), and the zeta potential was −11.7 mV.Figure 4Particle size distribution of synthesized silver nanoparticles (d.nm = diameter nanometre).Figure 4

Antibacterial activity of *Acinetobacter* nanoparticles {#sec3.4}
-------------------------------------------------------

The isolates *E. coli* (E3)*, P. aeruginosa* (P21), and *K. pneumoniae* (K32) were resistant to three classes of antibiotics, that is, β-lactams, aminoglycosides and quinolones ([Table 1](#tbl1){ref-type="table"}).Table 1Antibiotic sensitivity pattern of the tested isolates *E. coli* (E3)*, K. pneumoniae* (K32) and *P. aeruginosa* (P21).Table 1IsolateSusceptibility to antimicrobial agentsAPAUGAKFOXCAZPRLCIPTSGMIMI*E. coli (E3)*RRSRRSRRRR*K. pneumoniae* (K32)RRRRRRRRRR*P. aeruginosa* (P21)RRRRRRRRRR[^1]

The antimicrobial effects of the silver nanoparticles produced from *A. baumannii* against Gram-negative pathogens *E. coli, P. aeruginosa,* and *K. pneumoniae* derived from urinary tract infections were determined ([Table 2](#tbl2){ref-type="table"}). The MICs of silver nanoparticles were determined to be 3.125 μg/ml against *E. coli,* 1.56 μg/ml against *P. aeruginosa* and 3.125 μg/ml against *K. pneumoniae* compared to the control AgNO~3~ solution ([Table 2](#tbl2){ref-type="table"}).Table 2Minimal inhibitory concentrations (MICs) of the prepared silver nanoparticles, control AgNO~3~ (1 mM) and standard amoxicillin/clavulanic acid against *E. coli* (E3)*, K. pneumoniae* (K32) and *P. aeruginosa* (P21).Table 2Micro-organismMICs of *Acinetobacter* AgNPs (μg/ml)MICs of the control AgNO~3~ (μg/ml)MICs of amoxicillin/clavulanic acid (μg/ml)*E. coli* (E3)3.12510.631.25*P. aeruginosa* (P21)1.562.6563500*K. pneumoniae* (K32)3.12521.25437.5[^2]

Silver nanoparticles inhibited biofilm synthesis {#sec3.5}
------------------------------------------------

Acinetobacter silver nanoparticles eliminated the attachment and the formation of biofilm by the tested pathogenic organisms. [Figure 5](#fig5){ref-type="fig"} shows that low concentrations of silver nanoparticles significantly (*p* \< 0.01) reduced the attachments of *E. coli, K. pneumoniae* and *P. aeruginosa* by 66.6%, 75% and 86.5%, respectively, compared to the untreated control cultures.Figure 5Effects of *Acinetobacter* silver nanoparticles (AC AgNPs) on the attachment activities of *E. coli* (E3), *K. pneumoniae* (K32) and *P. aeruginosa* (P21) compared to the untreated, control bacteria (\* means a significant difference *p* \< 0.01).Figure 5

Discussion {#sec4}
==========

Infections due to multidrug-resistant pathogens represent a serious challenge for both hospitals and clinics. Bacterial biofilm formation is a critical mechanism for accumulation, and protection from antimicrobial therapy. Biofilm formation begins when microorganisms colonize medical devices, such as internal catheters, causing chronic infections.[@bib3] Resistant microbes are sometimes controlled by administration of high-doses of antibiotics which results in more adverse effects. Nano-size metallic materials represent a novel antimicrobial approach. Various types of nanoparticles and nanocarriers of antibiotics are efficient in treating infectious pathogens, biofilm formation and bacterial attachment.[@bib4]

Silver ions are reported to be effective against microbial infections and bacterial biofilm formation. Nevertheless, silver ions are characterized by low stability and high toxicity that hinder their clinical use. They are also easily inactivated through precipitation and complexation with salts.[@bib18] Therefore, silver in the nanoparticle format has been developed to overcome these limitations. Silver nanoparticles are characterized by high surface area and are associated with new chemical, physical and mechanical characteristics that are different from the ion or salt forms. The microbial approach for the synthesis of silver nanoparticles represents the optimal preparation method because it is a simple, biocompatible and cost effective method.[@bib19]

In our study, combining cell-free supernatants of *A. baumannii* with a silver nitrate solution resulted in a colour change into dark brown ([Figure 1](#fig1){ref-type="fig"}, [Figure 2](#fig2){ref-type="fig"}), which suggests the reduction of Ag ions into silver nanoparticles. This colour change is consistent with a previously reported method for extracellular synthesis of silver nanoparticles using *Bacillus* sp.[@bib20] Similarly, bacterial suspension of *Streptomyces* sp also reduces AgNO~3~ to silver nanoparticles with a colour change to brown.[@bib21] Similar extracellular synthesis of silver nanoparticles by *Fusarium semitectum* and *Aspergillus fumigatus* have also been reported.[@bib19] In a study by Kannan et al. (2011), the surface plasmon resonance of the biosynthesized AgNPs was observed at 390 nm and indicated small monodispersed particles.[@bib22]

The synthesis of silver nanoparticles was assessed using transmission electron microscopy, particle size measurements, and zeta potential ([Figure 3](#fig3){ref-type="fig"}, [Figure 4](#fig4){ref-type="fig"}). The synthesized silver nanoparticles were spherical and had sizes in the range of 37--168 nm. The variation in nanoparticle sizes may be attributed to the formation of particles at different time intervals. A variety of silver nanoparticle sizes, depending on the method of the production have been previously reported. Different shapes of silver nanoparticles have been observed however, the particles are predominantly of spherical shape.[@bib6] Silver nanoparticles from *A. fumigatus* have a diameter 15--45 nm and particles from *Streptomyces* sp. have a smaller size range from 15 to 25 nm.[@bib21] Silver nanoparticles synthesized from the white rot fungus *Pycnoporus sanguineus* have diameters between 52.8 and 103.3 nm.[@bib23] Additionally, silver nanoparticles in the present study showed high particle size potential around −11 mV, indicating that the particles have a low affinity for aggregation.[@bib15]

Additionally, the potential antibacterial activities of the synthesized nanoparticles were evaluated against multidrug-resistant pathogens ([Table 2](#tbl2){ref-type="table"}). The tested bacterial isolates were resistance to three classes of antibiotics, that is, β-lactams, aminoglycosides, and quinolones. The MICs of silver nanoparticles against Gram-negative bacteria were very low, which could be due to the small size of the synthesized particles in addition to the large surface area. Silver nanoparticles bind to bacterial cell membranes disturbing their permeability and cellular functions. Therefore, the small silver nanoparticles with large surface areas are more efficient than the larger silver nanoparticles.[@bib9] Silver nanoparticles with a smaller size range between 4 and 32 μg/ml are effective against Gram-positive, Gram-negative, and *Candida* sp.[@bib24] The MICs of silver nanoparticles synthesized from *Enterococcus faecalis* are 11 μg/ml, 3 μg/ml and 12 μg/ml against *K. pneumoniae*, *E. coli,* and *Staphylococcus aureus*, respectively.[@bib25]

Similarly, low concentrations of silver nanoparticles (1/4 MIC) significantly inhibited bacterial attachment and biofilm formation of the tested isolates ([Figure 4](#fig4){ref-type="fig"}). Likewise, biofilm formation by *P. aeruginosa* and *Staphylococcus epidermidis* are significantly lowered when treated with silver nanoparticles of size 100 nm.[@bib26] Dressings containing silver inhibit microbial adhesion and eliminate microbial infection.[@bib2] Chitosan-silver nanoparticles also eliminate foot infection caused due to multi-drug-resistant *P. aeruginosa* and *S. aureus*.[@bib8]

Conclusion {#sec5}
==========

These results suggest that silver nanoparticles may serve as effective anti-microbial and anti-biofilm agents against infections caused by multidrug-resistant isolates, which pose a serious threat to public health worldwide.

Recommendations {#sec6}
===============

An important aspect of future investigation is potentially expanding the application of the prepared nanoparticles by attaching powerful antibiotics to their surfaces. These antibiotics-loaded particles could actively and precisely destroy multi-resistant bacteria.
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[^1]: AP; ampicillin, AUG; amoxicillin/clavulanic acid, AK; amikacin, FOX; cefoxitin, CAZ; ceftazidime, CIP; ciprofloxacin TS; cotrimoxazole, PRL; piperacillin, GM; gentamicin and IMI; imipenem.

[^2]: AgNPs; silver nanoparticles.
